Author

Xiaopeng Peng

Observed names: Peng, Xiao-Peng, Peng, Xiaopeng, Xiao-Peng Peng

Institutions: Gannan Medical University, Southern Medical University

Observed institutions: Guangzhou University of Chinese Medicine, United States Naval Research Laboratory, Rochester Institute of Technology, Sun Yat-sen University, Guangdong Pharmaceutical University, Guangzhou University, Gannan Medical University, Dongguan People’s Hospital, Chinese Academy of Forestry, Research Institute of Forestry, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, State Key Laboratory of Tree Genetics and Breeding, Guangxi Key Laboratory of Clean Pulp and Papermaking and Pollution Control, Shenzhen Traditional Chinese Medicine Hospital, Zhaoqing Medical College, Southern Medical University

ORCID: 0000-0002-4434-0846

Observed ORCID: 0000-0002-4434-0846

OpenAlex ID: A5074653326

Recent Progress in Cyclic Aryliodonium Chemistry: Syntheses and Applications

2023 · Xiaopeng Peng, Abdur Rahim, et al. · Chemical Reviews · 142

Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment

2020 · Xiaopeng Peng, Zhiqiang Sun, et al. · European Journal of Medicinal Chemistry · 120

HDAC-targeting epigenetic modulators for cancer immunotherapy

2024 · Binbin Cheng, Wei Pan, et al. · European Journal of Medicinal Chemistry · 119

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies

2023 · Xiaopeng Peng, Zhihao Hu, et al. · Acta Pharmaceutica Sinica B · 89

Palladium catalyzed dual C–H functionalization of indoles with cyclic diaryliodoniums, an approach to ring fused carbazole derivatives

2014 · Yongcheng Wu, Xiaopeng Peng, et al. · Organic & Biomolecular Chemistry · 82

Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents

2021 · Xiaopeng Peng, Jingxuan Chen, et al. · Journal of Medicinal Chemistry · 74

Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma

2022 · Xiaopeng Peng, Ling Li, et al. · Journal of Medicinal Chemistry · 70

Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy

2022 · Xiaopeng Peng, Wanyi Pan, et al. · Pharmacological Research · 67

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

2023 · Deping Li, Xiaopeng Peng, et al. · European Journal of Medicinal Chemistry · 35

Synthesis of Fluorenes with an All‐Carbon Quaternary Center via Palladium‐Catalyzed Dual Arylation using Cyclic Diaryliodonium Triflates

2017 · Xiaopeng Peng, Hongwen Luo, et al. · Advanced Synthesis & Catalysis · 32

Pulsatility protects the endothelial glycocalyx during extracorporeal membrane oxygenation

2021 · Yu Zhang, Jianfeng Zeng, et al. · Microcirculation · 31

Recent advances in developing targeted protein degraders

2024 · Binbin Cheng, Hongqiao Li, et al. · European Journal of Medicinal Chemistry · 30

An Overview of HDAC Inhibitors and their Synthetic Routes

2019 · Xiaopeng Peng, Guochao Liao, et al. · Current Topics in Medicinal Chemistry · 30

Recent Progress in DNA Damage Response-Targeting PROTAC Degraders

2024 · Binbin Cheng, Xiaoting Fei, et al. · Journal of Medicinal Chemistry · 28

CDK12 orchestrates super‐enhancer‐associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer

2022 · Wei Dai, Junhong Wu, et al. · Clinical and Translational Medicine · 28

PDF

Copper-Catalyzed Selective Arylation of Nitriles with Cyclic Diaryl Iodonium Salts: Direct Access to Structurally Diversified Diarylmethane Amides with Potential Neuroprotective and Anticancer Activities

2020 · Xiaopeng Peng, Zhiqiang Sun, et al. · Organic Letters · 28

Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-κB activation

2023 · Junli Huang, Zeli Ma, et al. · European Journal of Medicinal Chemistry · 24

RETRACTED ARTICLE: Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma

2023 · Xiaopeng Peng, Ziwen Yu, et al. · Journal of Enzyme Inhibition and Medicinal Chemistry · 23

PDF

Synthesis of N‐Carbonyl Acridanes as Highly Potent Inhibitors of Tubulin Polymerization via One‐Pot Copper‐Catalyzed Dual Arylation of Nitriles with Cyclic Diphenyl Iodoniums

2020 · Xiaopeng Peng, Ling Li, et al. · Advanced Synthesis & Catalysis · 23

Decavanadate‐Catalyzed Oxidative Cross‐Dehydrogenative Coupling: an Efficient and Sustainable Approach toward P(O)─S Bond Formation

2025 · Jian Lei, Zhenliang Yu, et al. · Angewandte Chemie International Edition · 22

Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects

2024 · Zhiqiang Sun, Chenglong Xu, et al. · Journal of Medicinal Chemistry · 21

Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects

2022 · Xiaopeng Peng, Yichang Ren, et al. · Journal of Medicinal Chemistry · 20

Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents

2022 · Ling Li, Huiting Zhao, et al. · Bioorganic & Medicinal Chemistry · 19

Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024)

2024 · Binbin Cheng, Xianshi Ma, et al. · European Journal of Medicinal Chemistry · 18

Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases

2024 · Junli Huang, Zeli Ma, et al. · Journal of Medicinal Chemistry · 18

Works count: 76

Citation count: 1,439

H-index: 21

I10-index: 37